From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Investors should not worry like this, Can the home of "Crystal Methodist" really be so sanctimonious about a sex scandal?

By Chris Bailey of Financial Orbit | Sunday 6 February 2022


Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


It was a busy last week and it is going to be a busy next week too.  Such is this time of the year.  It’s all good fun.  Particularly entertaining – no doubt – will be the conference calls after full year updates from GlaxoSmithKline (GSK) and Unilever (ULVR).  Sensibly the former is splitting up its business, whilst the latter really should be considering it a bit more.  It will be enjoyable to listen to and react to (after all I own a bunch of shares in GlaxoSmithKline).  But today I wanted to talk about Rio Tinto (RIO)…

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

CTAI

Catenai – monster dilution

Time left: 05:35:44